The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until October 7, 2020.
Document
Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee, Renewal
The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissio...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 51464
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee, Renewal,” thefederalregister.org (October 11, 2018), https://thefederalregister.org/documents/2018-22183/advisory-committee-dermatologic-and-ophthalmic-drugs-advisory-committee-renewal.